查看文章

High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for the frontline treatment in younger patients with multiple myeloma (NDMM). 1–4 The achievement of complete response (CR) or at least very good partial response (VGPR) at the end of the ASCT procedure has been one of the key markers associated with an improved outcome. 5–7 In recent years, several strategies were paralleled to increase the CR plus VGPR rate in the ASCT paradigm that included improving the induction treatment, and more recently, the consolidation and the maintenance phases post ASCT. 3, 8 The high activity shown by immunomodulatory drugs and bortezomib-based regimens before ASCT has recently led to their use as consolidation and maintenance therapies. Several studies have demonstrated the impact of VTd on response rates and progression-free survival (PFS) either as …